Title

標靶藥物和免疫治療在葡萄膜炎疾病治療之角色

Translated Titles

The Role of Target Therapy and Immunotherapy in the Treatment of Uveitis

DOI

10.6320/FJM.202107_25(4).0010

Authors

陳彥慈(Yen-Tzu Chen);葉伯廷(Po-Ting Yeh)

Key Words

非感染性葡萄膜炎 ; 單株抗體 ; 免疫調節 ; non-infectious uveitis ; monoclonal antibody ; immunomodulation

PublicationName

台灣醫學

Volume or Term/Year and Month of Publication

25卷4期(2021 / 07 / 25)

Page #

512 - 515

Content Language

繁體中文

Chinese Abstract

非感染性葡萄膜炎的治療,主要使用皮質類固醇以及各類免疫抑制藥物,近年來快速研發的單株抗體類免疫調節藥物是未來相當有潛力的治療新選擇,這篇文章簡介數種單株抗體類免疫調節藥物及其相關臨床試驗的結果。

English Abstract

The management of non-infectious uveitis includes topical and systemic corticosteroid therapy and a variety of immunomodulatory agents. Immunomodulatory monoclonal antibodies are actively researched and may be applied to the treatment of non-infectious uveitis. This essay briefly introduced a few types of immunomodulatory monoclonal antibodies and the results of related clinical studies.

Topic Category 醫藥衛生 > 醫藥衛生綜合
Reference
  1. Trivedi A, Katelaris C. The use of biologic agents in the management of uveitis. Intern Med J 2019; 49:1352-63.
    連結:
  2. Papotto PH, Marengo EB, Sardinha LR, et al. Immunotherapeutic strategies in autoimmune uveitis. Autoimmun Rev 2014;13:909-16.
    連結:
  3. Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med 2016;375: 932-43.
    連結:
  4. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016; 388:1183-92.
    連結:
  5. Ramanan AV, Dick AD, Benton D, et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 2014;15:14.
    連結:
  6. Sharma SM, Fu DJ, Xue K. A review of the landscape of targeted immunomodulatory therapies for non-infectious uveitis. Ophthalmol Ther 2018;7:1-17.
    連結:
  7. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013;120: 777-87.
    連結:
  8. Sepah YJ, Sadiq MA, Chu DS, et al. Primary (month-6) outcomes of the stop-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol 2017;183:71-80.
    連結:
  9. Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (saril-niu): The phase 2 saturn study. Ophthalmology 2019;126:428-37.
    連結:
  10. Nguyen QD, Merrill PT, Clark WL, et al. Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA). Ophthalmology 2016;123: 2413-23.
    連結:
  11. Caspi RR. Immunotherapy of Uveitis: is gene therapy in our future? in uveitis and immunological disorders, U. Pleyer and C.S. Foster, Editors. Springer Berlin Heidelberg: Berlin, Heidelberg, 2007:193-210.
    連結:
  12. Nguyen QD, Sadiq MA, Soliman MK, et al. The effect of different dosing schedules of intravitreal sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc 2016;114:T3.